ArticleJournal of the Royal Statistical Society. Series A, (Statistics in Society)2022
COVID-19 clinical footprint to infer about mortality.
Article in Journal of the Royal Statistical Society. Series A, (Statistics in Society), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- COVID-19 clinical footprint to infer about mortality.Journal of the Royal Statistical Society. Series A, (Statistics in Society) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Information on 4.1 million patients identified as COVID-19 positive in Mexico is used to understand the relationship between comorbidities, symptoms, hospitalisations and deaths due to the COVID-19 disease. Using the presence or absence of these variables a clinical footprint for each patient is created. The risk, expected mortality and the prediction of death outcomes, among other relevant quantities, are obtained and analysed by means of a multivariate Bernoulli distribution. The proposal considers all possible footprint combinations resulting in a robust model suitable for Bayesian inference. The analysis is carried out considering the information on the monthly COVID-19 cases, from March 2020 to the first days of January 2022. This allows one to appreciate the evolution of the mortality risk over time and the effect the strategies of the health authorities have had on it. Supporting information for this article, containing code and the dataset used for the analysis, is available online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.